These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 66972)

  • 21. ABVD treatment of MOPP failures in Hodgkin's disease: a re-examination of goals of salvage therapy.
    Clamon GH; Corder MP
    Cancer Treat Rep; 1978 Mar; 62(3):363-7. PubMed ID: 77188
    [No Abstract]   [Full Text] [Related]  

  • 22. MOPP treatment of resistant Hodgkin's disease following ABVD failure.
    Cimino G; Anselmo AP; Marzullo A; Maurizi Enrici R; Mauro F; Papa G; Mandelli F
    Tumori; 1983 Oct; 69(5):469-72. PubMed ID: 6196891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).
    Papa G; Mandelli F; Anselmo AP; De Luca AM; Maurizienrici R; Mauro F; Testi AM; Amadori S; Biagini C
    Eur J Cancer Clin Oncol; 1982 Sep; 18(9):803-6. PubMed ID: 6185342
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe.
    Harker WG; Kushlan P; Rosenberg SA
    Ann Intern Med; 1984 Oct; 101(4):440-6. PubMed ID: 6206757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture.
    Bonadonna G
    Cancer Res; 1982 Nov; 42(11):4309-20. PubMed ID: 6181867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure.
    Porzig KJ; Portlock CS; Robertson A; Rosenberg SA
    Cancer; 1978 May; 41(5):1670-5. PubMed ID: 77180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vancouver hybrid: preliminary experience in the treatment of Hodgkin's disease in childhood and adolescence.
    Khan SP; Gilchrist GS; Arndt CA; Smithson WA; Chen MG; Schomberg PJ; Matsumoto JM; O'Fallon WM
    Mayo Clin Proc; 1994 Oct; 69(10):949-54. PubMed ID: 7523802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Greater curability in advanced Hodgkin's disease?
    Portlock CS
    Cancer J Sci Am; 1999; 5(5):264-5. PubMed ID: 10526665
    [No Abstract]   [Full Text] [Related]  

  • 30. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease.
    Santoro A; Bonfante V; Bonadonna G
    Ann Intern Med; 1982 Feb; 96(2):139-43. PubMed ID: 6174060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bleomycin (NSC-125066) and CCNU (NSC-79037) in the combination chemotherapy of mopp-resistant hodgkin's disease.
    Kurnick JE; White M; Ware DE; Robinson WA
    Cancer Chemother Rep; 1975; 59(6):1147-50. PubMed ID: 56989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combinaed chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP.
    Bloomfield CD; Weiss RB; Fortuny I; Vosika G; Kennedy BJ
    Cancer; 1976 Jul; 38(1):42-8. PubMed ID: 947533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
    Takenaka T; Mikuni C; Miura A; Sasaki T; Suzuki H; Hotta T; Hirano M; Fukuhara S; Sugiyama H; Nasu K; Dohi H; Kozuru M; Tomonaga M; Tajima K; Niimi M; Fukuda H; Mukai K; Shimoyama M
    Jpn J Clin Oncol; 2000 Mar; 30(3):146-52. PubMed ID: 10798542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB).
    Wiernik PH; Schiffer CA
    J Cancer Res Clin Oncol; 1988; 114(1):105-7. PubMed ID: 2450876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease.
    Connors JM; Klimo P
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):35-40. PubMed ID: 2438780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
    Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
    Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy for stage IV Hodgkin's disease (Report no 14).
    Goldman JM
    Clin Radiol; 1981 Sep; 32(5):531-6. PubMed ID: 6168426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug selection in the treatment of Hodgkin's disease.
    Bonadonna G; Santoro A
    Hematol Oncol; 1983; 1(1):3-12. PubMed ID: 6203820
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.